Short-term Pregnancy Outcomes After Nirmatrelvir–Ritonavir Treatment for Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
Sign Up to like & getrecommendations! Published in 2022 at "Obstetrics and Gynecology"
DOI: 10.1097/aog.0000000000004900
Abstract: Most pregnant patients who received nirmatrelvir–ritonavir treatment for mild-to-moderate coronavirus disease 2019 (COVID-19) tolerated treatment without adverse effects. This is a descriptive study of pregnant patients who received nirmatrelvir–ritonavir therapy from April 16, 2022, through… read more here.
Keywords: mild moderate; moderate coronavirus; nirmatrelvir ritonavir; ritonavir treatment ... See more keywords